Constellate Proteomics
Delft, Netherlands
◆ About Constellate Proteomics
A Delft-based deeptech company that builds single-molecule tools to help biopharma teams judge the quality of antibody-producing cell lines earlier in development.
◆ What sets it apart
Its single-molecule TIRF platform combines multiple antibody quality analyses from a small amount of crude, unpurified sample, enabling actionable clone screening in the first week rather than weeks later.
◆ Sectors
◆ Business
Modelhardware
CustomerBiopharmaceutical companies and contract development and manufacturing organizations developing antibody-based therapeutics and production cell lines
◆ Notable
- Spun out from TU Delft in February 2026
- Selected for the imec.istart deep-tech accelerator
- Won the Academic Startup Competition
- Validated titre and glycosylation probes and opened pilot projects with biopharma and CDMO samples
◆ Backing funds on Raise
- Graduate Venturespre-seed
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Constellate Proteomics do?
A Delft-based deeptech company that builds single-molecule tools to help biopharma teams judge the quality of antibody-producing cell lines earlier in development.
Where is Constellate Proteomics based?
Constellate Proteomics is based in Delft, Netherlands, founded in 2026.
Who has invested in Constellate Proteomics?
Investors in Constellate Proteomics include Graduate Ventures, Tech Scout Venture Fund and imec.istart.